Literature DB >> 15885553

[Management of phenylketonuria and hyperphenylalaninemia: the French guidelines].

V Abadie1, J Berthelot, F Feillet, N Maurin, A Mercier, H Ogier de Baulny, L de Parscau.   

Abstract

Phenylketonuria (PKU) is an inherited metabolic disease affecting about one birth out of 15 000. From 1978, a national systematic neonatal screening was set up in France with a regional organisation. French rational and guidelines have been established by the national PKU group with the collaboration of all the physicians responsible for the regional centres. These guidelines specify the minimal diagnosis procedures leading to an optimal treatment of all patients. A low-phenylalanine diet must be started as soon as possible in the neonatal period for all newborns whose phenylalanine levels are above 10 mg/dl. The dietary control must keep the phenylalanine plasma levels between 2 and 5 mg/dl until 10 years of age. After this age, several data argue for a progressive and controlled relaxation of the diet, keeping the phenylalanine level below 15 mg/dl until the end of the adolescence and below 20 to 25 mg/dl in adulthood. All PKU patients must be followed up for life, in order to screen those who may not bear the diet relaxation and in order to strictly prevent maternal PKU deleterious consequences.

Entities:  

Mesh:

Year:  2005        PMID: 15885553     DOI: 10.1016/j.arcped.2005.02.004

Source DB:  PubMed          Journal:  Arch Pediatr        ISSN: 0929-693X            Impact factor:   1.180


  13 in total

1.  Lessons from 30 years of selective screening for tetrahydrobiopterin deficiency.

Authors:  Jean-Louis Dhondt
Journal:  J Inherit Metab Dis       Date:  2010-05-11       Impact factor: 4.982

2.  Screening of three Mediterranean phenylketonuria mutations in Tunisian families.

Authors:  Sameh Khemir; Hajer Siala; Sameh Hadj Taieb; Wafa Cherif; Hatem Azzouz; Rym Kéfi; Sonia Abdelhak; Naziha Khouja; Neji Tebib; Taieb Massaoud; Marie Françoise Ben Dridi; Naziha Kaabachi
Journal:  J Genet       Date:  2012       Impact factor: 1.166

3.  Musty odour, mental retardation, and spastic paraplegia revealing phenylketonuria in adulthood.

Authors:  Guillemette Jousserand; Jean-Christophe Antoine; Jean-Philippe Camdessanché
Journal:  J Neurol       Date:  2009-10-28       Impact factor: 4.849

4.  Outcomes of phenylketonuria with relevance to follow-up.

Authors:  F J van Spronsen; A Bélanger-Quintana
Journal:  JIMD Rep       Date:  2011-06-22

5.  Nutritional Management of Phenylketonuria.

Authors:  Erin L Macleod; Denise M Ney
Journal:  Ann Nestle Eng       Date:  2010-06

Review 6.  Food products made with glycomacropeptide, a low-phenylalanine whey protein, provide a new alternative to amino Acid-based medical foods for nutrition management of phenylketonuria.

Authors:  Sandra C van Calcar; Denise M Ney
Journal:  J Acad Nutr Diet       Date:  2012-08       Impact factor: 4.910

Review 7.  The truth of treating patients with phenylketonuria after childhood: the need for a new guideline.

Authors:  F J van Spronsen; P Burgard
Journal:  J Inherit Metab Dis       Date:  2008-08-12       Impact factor: 4.982

8.  Effects and clinical significance of tetrahydrobiopterin supplementation in phenylalanine hydroxylase-deficient hyperphenylalaninaemia.

Authors:  G Gramer; P Burgard; S F Garbade; M Lindner
Journal:  J Inherit Metab Dis       Date:  2007-08-06       Impact factor: 4.982

9.  Dietary habits and metabolic control in adolescents and young adults with phenylketonuria: self-imposed protein restriction may be harmful.

Authors:  A M Das; K Goedecke; U Meyer; N Kanzelmeyer; S Koch; S Illsinger; T Lücke; H Hartmann; K Lange; H Lanfermann; L Hoy; X-Q Ding
Journal:  JIMD Rep       Date:  2013-11-13

10.  Diurnal variation of phenylalanine and tyrosine concentrations in adult patients with phenylketonuria: subcutaneous microdialysis is no adequate tool for the determination of amino acid concentrations.

Authors:  Sarah C Grünert; Corinna M Brichta; Andreas Krebs; Hans-Willi Clement; Reinhold Rauh; Christian Fleischhaker; Klaus Hennighausen; Jörn Oliver Sass; K Otfried Schwab
Journal:  Nutr J       Date:  2013-05-14       Impact factor: 3.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.